Canadian spotlight 11.1: 
Key additions from the first half of November 2021

In the first half of November, contributing Canadian evidence-synthesis teams have shared with us 10 newly completed evidence syntheses which are listed in the table below. One of these syntheses provide insights across all domains of the COVID-END taxonomy (public-health measures, clinical management, health-system arrangements, and economic and social response), and one synthesis provides insight across two domains (public-health measures and health-system arrangements). The remaining focus on public-health measures (n=6), and clinical management (n=2).

<table>
<thead>
<tr>
<th>Taxonomy section</th>
<th>Title</th>
<th>Type of product</th>
<th>Date of last search (and publication)</th>
<th>Evidence synthesis team</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Clinical management</td>
<td>What are the implications of SARS-CoV-2 variants for public-health measures and health-system arrangements?</td>
<td>Update to a living evidence synthesis</td>
<td>2021-10-22 (published 2021-11-03)</td>
<td>School of Nursing, Dalhousie University</td>
</tr>
<tr>
<td>• Health-system arrangements</td>
<td>What evidence exists on the social and economic considerations for rapid diagnostic testing for COVID-19?</td>
<td>Update to a living rapid review</td>
<td>2021-11-03 (published 2021-11-09)</td>
<td>Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute</td>
</tr>
<tr>
<td>• Public-health measures</td>
<td>What is the efficacy and effectiveness of available COVID-19 vaccines for variants of concern?</td>
<td>Update to a living evidence synthesis</td>
<td>2021-11-03 (published 2021-11-03)</td>
<td>Health Information Research Unit, McMaster University</td>
</tr>
<tr>
<td>Category</td>
<td>Description</td>
<td>Type</td>
<td>Date</td>
<td>Source</td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------</td>
<td>--------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Public-health measures</td>
<td><strong>Rapid review update 1: What is the ongoing effectiveness, immunogenicity, and safety of COVID-19 vaccines in persons who have had a prior, confirmed COVID-19 infection?</strong></td>
<td>Rapid review</td>
<td>2021-10-15</td>
<td>National Collaborating Centre for Methods and Tools (NCCMT)</td>
</tr>
<tr>
<td>Public-health measures</td>
<td><strong>How effective are COVID-19 vaccines?</strong></td>
<td>Update to a living rapid review</td>
<td>2021-10-14</td>
<td>Alberta Health Services</td>
</tr>
<tr>
<td>Public-health measures</td>
<td>Evergreen rapid review on COVID-19 vaccine attitudes and uptake in Canada – Update 11 (For those interested in accessing the full copy of the rapid review, please contact <a href="mailto:phac.ocsoevidence-bcsdonnaeesprobantes.aspc@canada.ca">phac.ocsoevidence-bcsdonnaeesprobantes.aspc@canada.ca</a>)</td>
<td>Update to a living evidence review</td>
<td>Not stated (published 2021-10-18)</td>
<td>Emerging Science Group, Public Health Agency of Canada (PHAC)</td>
</tr>
<tr>
<td>Public-health measures</td>
<td>Living summary of SARS-CoV-2 variants of concern: The Delta variant (B.1.617.2) profile (For those interested in accessing the full copy of the rapid review, please contact <a href="mailto:phac.ocsoevidence-bcsdonnaeesprobantes.aspc@canada.ca">phac.ocsoevidence-bcsdonnaeesprobantes.aspc@canada.ca</a>)</td>
<td>Living evidence review</td>
<td>Not stated (published 2021-09-15)</td>
<td>Emerging Science Group, Public Health Agency of Canada (PHAC)</td>
</tr>
<tr>
<td>Clinical management</td>
<td><strong>What is the incidence, associated risk factors, and clinical course of myocarditis and pericarditis following COVID-19 vaccination?</strong></td>
<td>Rapid review</td>
<td>2021-10-06</td>
<td>Alberta Research Centre for Health Evidence (ARCHE) and Cochrane Child Health Field, University of Alberta</td>
</tr>
<tr>
<td>Clinical management</td>
<td>Evidence on the virulence, transmission and impact of B.1.617.2 (Delta) among children, update 1 (For those interested in accessing the full copy of the rapid review, please contact <a href="mailto:phac.ocsoevidence-bcsdonnaeesprobantes.aspc@canada.ca">phac.ocsoevidence-bcsdonnaeesprobantes.aspc@canada.ca</a>)</td>
<td>Living evidence review</td>
<td>Not stated (published 2021-10-08)</td>
<td>Emerging Science Group, Public Health Agency of Canada (PHAC)</td>
</tr>
</tbody>
</table>